Supplementary Data 1 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Year: 2023
Type: supplementary-materials
Abstract: This figure presents a consort diagram showing (A) the dose-escalation scheme for BMS-936564 (ulocuplumab), (B) the dose-expansion scheme, including Arms A & B, of the study and (C) Number of patients at each dose level in the phase I and II studies and in arms A and B.
Authors: Irene M. Ghobrial, Chia-Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael D. Robbins, Pamela S. Becker
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361967485